Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
17 studies found for:    PM01183
Show Display Options
Rank Status Study
1 Completed Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Condition: ADVANCED SOLID TUMORS
Intervention: Drug: PM01183
2 Completed Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Condition: Acute Leukemia
Intervention: Drug: PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
3 Completed Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: lurbinectedin (PM01183);   Drug: Cisplatin
4 Completed Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
Condition: Major Advanced Solid Tumors Other Than Colorectal
Intervention: Drug: PM01183
5 Recruiting A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: PM01183
6 Recruiting Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: lurbinectedin ( PM01183);   Drug: Irinotecan
7 Completed Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
Conditions: Metastatic Breast Cancer;   Pancreatic Cancer;   Metastatic Colorectal Cancer
Interventions: Drug: lurbinectedin (PM01183);   Drug: capecitabine
8 Completed Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
Condition: Specific Advanced Solid Tumors
Interventions: Drug: lurbinectedin (PM01183);   Drug: Gemcitabine
9 Recruiting Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: lurbinectedin (PM01183)
10 Completed Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Conditions: Breast Cancer;   Ovarian Cancer;   Gynecological Cancer;   Head and Neck Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Non-squamous Cell Lung Cancer
Intervention: Drug: PM01183 + paclitaxel +/- bevacizumab
11 Active, not recruiting Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Conditions: Endometrial Adenocarcinomas;   Neuroendocrine Tumors;   Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Interventions: Drug: lurbinectedin (PM01183);   Drug: Doxorubicin
12 Completed Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
Condition: Solid Tumors
Intervention: Drug: lurbinectedin (PM01183)
13 Active, not recruiting A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Condition: Metastatic Sarcoma
Interventions: Drug: PM01183;   Drug: Doxorubicin;   Drug: Gemcitabine
14 Active, not recruiting Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Drug: Lurbinectedin (PM01183);   Drug: Pegylated liposomal doxorubicin (PLD);   Drug: Topotecan
15 Recruiting Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
Condition: Advanced Solid Tumors.
Intervention: Drug: PM01183 + olaparib
16 Completed A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Lurbinectedin (PM01183)
17 Recruiting Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
Condition: Small-cell Lung Cancer
Interventions: Drug: Lurbinectedin (PM01183);   Drug: Doxorubicin (DOX);   Drug: Cyclophosphamide (CTX);   Drug: Vincristine (VCR);   Drug: Topotecan

Study has passed its completion date and status has not been verified in more than two years.